Back to CVE records
Critical 9.8Published Jul 20, 2026

CVE-2026-62183Improper Privilege Management vulnerability in Apache Syncope.

Updated under an hour ago ()

Does this affect you?

It affects apache syncope. Add what you run to find out whether that includes you.

No exploitation reported and no EPSS estimate yet.

Improper Privilege Management vulnerability in Apache Syncope. When: * the all-Java user workflow adapter is configured, or * the Flowable user workflow adapter is configured, bearing a BPMN definition not requiring admin approval for user self registration of self update requests the following scenario could happen. A REST API call can allow the user to grant themselves one or more of defined Roles, thus gaining their Entitlements and becoming in fact an administrator; the actual Entitlements gained depend on the Roles that are effectively defined on the specific Syncope deployment. This issue affects Apache Syncope: from 3.0.0-M0 through 3.0.16, from 4.0.0-M0 Through 4.0.6, from 4.1.0-M0 through 4.1.1. Users are recommended to upgrade to version 4.0.7 / 4.1.2, which fix this issue.

CVSS
9.8 CRITICAL (v3.1, NVD)CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H
Weakness (CWE)
CWE-269
Known exploited
Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days)
Not loaded for this CVE
Assigned by
Not given
NVD analysis
Analyzed
Record last updated
Jul 27, 2026
First seen by InfoSec Signals
Oct 9, 2026

Affected products

Affected products
apache syncope
apache:syncope
from 3.0.0 through 3.0.16; from 4.0.0 before 4.0.7; from 4.1.0 before 4.1.2
NVD

References

  • mailing-list, vendor-advisory
  • mailing-list, third-party-advisory

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.